FDA Grand Rounds: Ethnicity- and Gender-related Differences in Alzheimer’s Disease—January 11, 2018

FDA Grand Rounds

Minorities and women are particularly vulnerable to Alzheimer’s disease (AD). Women have a higher incidence of AD at later ages and relative to Caucasians, the threat of AD is even more substantial in the African-American and Hispanic communities. More research into African Americans and other minority populations with AD is crucial to the goals of precision medicine. Studies show the advantage of using different approaches to understanding what is likely to be a complex picture of AD-related ethnicity differences.

This presentation will discuss research into protein levels in post-mortem African American and Caucasian brain tissue from both genders to explore ethnicity- and gender-related differences. The selected proteins include those thought to be critically involved in AD. Those proteins were examined in samples of the middle temporal gyrus that were matched for age at death since this region is critically involved in language processing and generation and has been shown to be significantly affected by AD.

Presented by
Sherry Ferguson, PhD
Research Psychologist
Division of Neurotoxicology
FDA’s National Center for Toxicological Research (NCTR)

Vijayalakshmi Varma, PhD
Research Biologist, NCTR

Thursday, Jan. 11, 2018
12:00 pm to 1:00 pm
Learn more and register here.

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute presentation is followed by questions from the audience.